iData Insights

Onxeo SA - Product Pipeline Review – 2015 Is Released

Press Release   •   Feb 04, 2016 15:52 IST

This report provides comprehensive information on the current therapeutic developmental pipeline of Onxeo SAs, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Onxeo SA including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Onxeo SAs human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Onxeo SAs pipeline products Reasons to buy - Evaluate Onxeo SAs strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Onxeo SA in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Onxeo SAs R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Onxeo SA and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Onxeo SA - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Onxeo SA and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues

Browse Complete Report with TOC http://www.idatainsights.com/reports-landing-page.php?id=179126/onxeo-sa-product-pipeline-review-2015

To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landing-page.php?id=179126/onxeo-sa-product-pipeline-review-2015

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Onxeo SA Snapshot 5

Onxeo SA Overview 5

Key Information 5

Key Facts 5

Onxeo SA - Research and Development Overview 6

Key Therapeutic Areas 6

Onxeo SA - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Out-Licensed Products 11

Out-Licensed Products/Combination Treatment Modalities 12

Onxeo SA - Pipeline Products Glance 13

Onxeo SA - Late Stage Pipeline Products 13

Pre-Registration Products/Combination Treatment Modalities 13

Phase III Products/Combination Treatment Modalities 14

Onxeo SA - Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Phase I Products/Combination Treatment Modalities 16

Onxeo SA - Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

Onxeo SA - Drug Profiles 19

acyclovir 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

doxorubicin 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

miconazole nitrate 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

belinostat 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

clonidine hydrochloride ER 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

BA-016 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

BA-026 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

irinotecan hydrochloride 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Onxeo SA - Pipeline Analysis 30

Onxeo SA - Pipeline Products by Target 30

Onxeo SA - Pipeline Products by Route of Administration 31

Onxeo SA - Pipeline Products by Molecule Type 32

Onxeo SA - Pipeline Products by Mechanism of Action 33

Onxeo SA - Recent Pipeline Updates 34

Onxeo SA - Dormant Projects 49

Onxeo SA - Discontinued Pipeline Products 50

Discontinued Pipeline Product Profiles 50

CHS-828 50

BA-032 50

Onxeo SA - Locations And Subsidiaries 51

Head Office 51

Other Locations & Subsidiaries 51

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53" width="80" height="40" />Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Onxeo SA Snapshot 5

Onxeo SA Overview 5

Key Information 5

Key Facts 5

Onxeo SA - Research and Development Overview 6

Key Therapeutic Areas 6

Onxeo SA - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Out-Licensed Products 11

Out-Licensed Products/Combination Treatment Modalities 12

Onxeo SA - Pipeline Products Glance 13

Onxeo SA - Late Stage Pipeline Products 13

Pre-Registration Products/Combination Treatment Modalities 13

Phase III Products/Combination Treatment Modalities 14

Onxeo SA - Clinical Stage Pipeline Products 15

Phase II Products/Combination Treatment Modalities 15

Phase I Products/Combination Treatment Modalities 16

Onxeo SA - Early Stage Pipeline Products 17

Preclinical Products/Combination Treatment Modalities 17

Discovery Products/Combination Treatment Modalities 18

Onxeo SA - Drug Profiles 19

acyclovir 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

doxorubicin 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

miconazole nitrate 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

belinostat 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

clonidine hydrochloride ER 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

BA-016 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

BA-026 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

irinotecan hydrochloride 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

Onxeo SA - Pipeline Analysis 30

Onxeo SA - Pipeline Products by Target 30

Onxeo SA - Pipeline Products by Route of Administration 31

Onxeo SA - Pipeline Products by Molecule Type 32

Onxeo SA - Pipeline Products by Mechanism of Action 33

Onxeo SA - Recent Pipeline Updates 34

Onxeo SA - Dormant Projects 49

Onxeo SA - Discontinued Pipeline Products 50

Discontinued Pipeline Product Profiles 50

CHS-828 50

BA-032 50

Onxeo SA - Locations And Subsidiaries 51

Head Office 51

Other Locations & Subsidiaries 51

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

Read More http://www.idatainsights.com/reports-landing-page.php?id=179126/onxeo-sa-product-pipeline-review-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.